CureVac AG. (2/4/19). "Press Release: CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical". Tübingen & Boston, MA.

	Organisation	CureVac AG
	Today	CureVac SE
	Group	CureVac (Group)
	Organisation 2	Sandoz AG
	Today	Novartis AG (NYSE: NVS)
	Group	Novartis (Group)
	Product	preclinical research
	Product 2	mRNA-based drug
	Person	Mueller, Stefan (CureVac 201902– VP Preclinical before Sandoz Biopharmaceuticals + Merck Serono + Merck + Knoll GmbH)
	Person 2	Voliotis, Dimitris (CureVac 201901– CDO before Eisai Inc + 12years at Bayer HealthCare)

Drug development veteran to focus on advancing the company’s preclinical portfolio of programs in naturally optimized mRNA

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today the appointment of Stefan Mueller, Ph.D., as Vice President Preclinical. Dr. Mueller will oversee preclinical programs across CureVac’s pipeline from drug discovery to Investigational New Drug (IND) filing. His appointment augments the recent hiring of Dimitris Voliotis, M.D., Dr. med. as Chief Development Officer and bolsters CureVac’s commitment to aggressively develop and advance assets to help positively transform the lives of patients.

“I am very pleased to welcome Dr. Stefan Mueller to the CureVac team,” said Dr. Dimitris Voliotis, Chief Development Officer, CureVac. “With Dr. Mueller’s expertise in early-stage drug development, we are able to broaden our approach to preclinical programs and determine the best path forward for our naturally optimized mRNA candidates across our oncology, molecular therapy and prophylactic vaccine pipelines.”

Dr. Mueller will be responsible for rapidly advancing CureVac’s preclinical pipeline and will report to Dr. Dimitris Voliotis. Prior to joining CureVac, Dr. Mueller was most recently Global Program Leader for Rituximab biosimilar (Rixathon®) at Sandoz Biopharmaceuticals. Other previous experience includes positions at Merck Serono, Merck, and Knoll GmbH, focusing in the areas of toxicology, drug discovery, and early drug development. Dr. Mueller was awarded his Ph.D. from University of Würzburg in 1997.

“It is an honor to join CureVac during this exciting time in the field of mRNA science,” said Dr. Stefan Mueller, Vice President Preclinical, CureVac. “CureVac is leading the way with its mRNA technology and I look forward to utilizing it to better define preclinical product candidates that advance our mission to revolutionize human health through the unlimited possibilities of mRNA.”

Dr. Mueller joined CureVac on February 1, 2019 and is based at the company’s Tübingen, Germany headquarters.

About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. To date, CureVac has received approximately $420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp’s Dievini and an investment of $52 million from the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, Arcturus Therapeutics, Acuitas, and the Bill & Melinda Gates Foundation.

For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.

***

Media Contact

Jenn Gordon, Media Relations Global Health PR, New York, United States T: +1 202-587-2580 jgordon@globalhealthpr.com

Investor Contact

Matthew Beck, Vice President Investor Relations CureVac AG, Boston, MA, United States T: +1 917-415-1750 matthew.beck@curevac.com

Record changed: 2023-06-05